Category Archives: Cell Therapy

Growth Analysis Report onAnimal Stem Cell Therapy Market size | Industry Segment by Applications (Veterinary Hospitals and Research Organizations), by Type (Dogs, Horses and Others), Regional Outlook, Market Demand, Latest Trends, Animal Stem Cell Therapy Industry Share & Revenue by Manufacturers, Company Profiles, Growth Forecasts 2025.Analyzes current market size and upcoming 5 years growth of this industry.

TheAnimal Stem Cell TherapyMarketAnalysis report attempts to offer foremost and deep understandings into the current market scenario and the advanced development dynamics. The report onAnimal Stem Cell Therapy Marketaims to provides the extensive view of the market landscape. The comprehensive research will enable the well-established as well as the emerging players to expand their business approaches and achieve their targeted goals.

This report on Animal Stem Cell Therapy Market covers the manufacturers data including shipment, revenue, gross profit, business distribution etc., these data help the consumer know about the competitors better. This report also covers topmost regions and countries of the world, which shows a regional development status, including Animal Stem Cell Therapy market size, volume and value as well as price data.

Request Sample Copy of this Report @ https://www.express-journal.com/request-sample/41316

List of Major Key playersoperating in the Animal Stem Cell Therapy Market are:

The objectives of this report are:

Animal Stem Cell Therapy Market Segmentation by Product Type:

Industry Segmentation by end user:

Most significant topics covered in Animal Stem Cell Therapy market report are:

The foremost points are labelled in detail which are covered in this Animal Stem Cell Therapy Market Report:

Request Customization on This Report @ https://www.express-journal.com/request-for-customization/41316

Go here to see the original:
Animal Stem Cell Therapy Market Forecast 2020-2025, Latest Trends and Opportunities - Express Journal

New Jersey, United States:The new report has been added by Market Research Intellect to provide a detailed overview of the Cell Therapy Market. The study will help to better understand the Cell Therapy industry competitors, the sales channel, Cell Therapy growth potential, potentially disruptive trends, Cell Therapy industry product innovations and the value / volume of size market (regional / national level, Cell Therapy- Industrial segments), market share of the best actors / products.

Information has been added to the report to provide a realistic view of the industry based on data from Cell Therapy manufacturers, i.e. H. Shipping, price, sales, gross profit, business distribution, etc., SWOT analysis, consumer preference, current developments and trends, drivers and limiting factors, company profile, investment opportunities, analysis of the demand gap, market size value / volume, services and products, Porters five models , socio-economic factors, official regulations in the Cell Therapy branch. Market participants can use the report to take a look at the future of the Cell Therapy market and make significant changes to their operating style and marketing tactics in order to achieve sustainable growth.

Get | Download Sample Copy @ https://www.marketresearchintellect.com/download-sample/?rid=149184&utm_source=SI&utm_medium=888

The report examines the competitive environment scenario observed with key players in Cell Therapy sales, the profile of their business, their earnings, their sales, their business tactics, and the forecasting situations of the Cell Therapy sales industry. According to studies, the Cell Therapy sales market is very competitive and diverse due to global and local suppliers.

The Cell Therapy Sales Market Report mainly contains the following Manufacturers:

Market Competition

The competitive landscape of the Cell Therapy market is examined in detail in the report, with a focus on the latest developments, the future plans of the main players and the most important growth strategies that they have adopted. The analysts who compiled the report have created a portrait of almost all of the major players in the Cell Therapy market, highlighting their key commercial aspects such as production, areas of activity and product portfolio. All companies analyzed in the report are examined on the basis of important factors such as market share, market growth, company size, production, sales and earnings.

Report Highlights

Assessment of sales channels

innovation trends

sustainability strategies

Niche market trends

Market entry analysis

market size and forecast

The geographic department provides data that give you an overview of the turnover of companies and sales figures for the growth activity Cell Therapy for electrical meters. Here are the strengths of the geographic divisions: North America (United States, Canada and Mexico), Europe (Germany, Spain, France, Great Britain, Russia and Italy and more), Asia-Pacific (China, Japan, Korea, India and Southeast Asia) and more ), South America (Brazil, Argentina, Colombia), the Middle East and Africa (Saudi Arabia, United Arab Emirates, Egypt, Nigeria and South Africa) and ROW.

Ask For Discount (Special Offer: Get 25% discount on this report) @ https://www.marketresearchintellect.com/ask-for-discount/?rid=149184&utm_source=SI&utm_medium=888

Table of Content

1 Introduction of Cell Therapy Market1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Cell Therapy Market Outlook4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Cell Therapy Market, By Deployment Model5.1 Overview

6 Cell Therapy Market, By Solution6.1 Overview

7 Cell Therapy Market, By Vertical7.1 Overview

8 Cell Therapy Market, By Geography8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Cell Therapy Market Competitive Landscape9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix11.1 Related Research

Complete Report is Available @ https://www.marketresearchintellect.com/product/global-cell-therapy-market-size-and-forecast/?utm_source=SI&utm_medium=888

We also offer customization on reports based on specific client requirement:

1-Freecountry level analysis forany 5 countriesof your choice.

2-FreeCompetitive analysis of any market players.

3-Free 40 analyst hoursto cover any other data points

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven FernandesMarket Research IntellectNew Jersey ( USA )Tel: +1-650-781-4080

Email: [emailprotected]

Get Our Trending Report

https://www.marketresearchblogs.com/

https://www.marktforschungsblogs.com/

Tags: Cell Therapy Market Size, Cell Therapy Market Growth, Cell Therapy Market Forecast, Cell Therapy Market Analysis, Cell Therapy Market Trends, Cell Therapy Market

See the original post here:
Cell Therapy Market Size Analysis, Top Manufacturers, Shares, Growth Opportunities and Forecast to 2026 - Science In Me

PERTH, Australia Australian stem cell therapy company Mesoblast Ltd. announced that the FDA gave it the green light to test its allogeneic mesenchymal stem cell (MSC) product candidate remestemcel-L in patients with acute respiratory distress syndrome (ARDS) caused by coronavirus (COVID-19).

Were going to be evaluating whether an injection of our cells intravenously can tone down the immune system just enough so it gets rid of the virus but doesnt destroy your lungs at the same time, Mesoblast CEO Silviu Itescu told BioWorld.

What people are dying of is acute respiratory distress syndrome, which is the bodys immune response to the virus in the lungs, and the immune system goes haywire, and in its battle with the virus it overreacts and causes severe damage to the lungs, Itescu said.

The FDA clearance provides a pathway in the United States for use of remestemcel-L in patients with COVID-19 ARDS, where the prognosis is very dismal, under both expanded access compassionate use and in a planned randomized controlled trial.

The company is in active discussions with various governments, regulatory authorities, medical institutions and pharmaceutical companies.

Recently published results from an investigator-initiated clinical study conducted in China reported that allogeneic MSCs cured or significantly improved functional outcomes in all seven treated patients. A post-hoc analysis of a randomized, placebo-controlled study in 60 patients with chronic obstructive pulmonary disease demonstrated that remestemcel-L significantly improved respiratory function in patients with the same elevated inflammatory biomarkers that are also observed in patients with COVID-19 ARDS.

Remestemcel-L is being developed for various inflammatory conditions and is believed to counteract the inflammatory processes implicated in those diseases by down-regulating the production of pro-inflammatory cytokines, increasing production of anti-inflammatory cytokines, and enabling recruitment of naturally occurring anti-inflammatory cells to involved tissues.

The safety and therapeutic effects of remestemcel-L intravenous infusions have been evaluated in more than 1,100 patients in various clinical trials.

The stem cell therapy was successful in a phase III trial for steroid-refractory acute graft-vs.-host disease (aGVHD) in children, a potentially fatal inflammatory condition due to a similar cytokine storm process as is seen in COVID-19 ARDS.

Cynata in preclinical ARDs studies

Fellow Aussie regenerative medicine company Cynata Therapeutics Ltd. is studying the utility of its Cymerus MSCs as a treatment for ARDS associated with COVID-19 with the Critical Care Research Group at Prince Charles Hospital in Brisbane, Australia.

Acute respiratory distress syndrome is a huge problem worldwide and is prevalent aside from COVID-19, but suddenly it is on the front page because people are dying of this. The data behooves us to see if MSC treatment can rescue people from this, Cynata CEO Ross Macdonald told BioWorld.

The Critical Care Research Group has long seen the need to improve interventions in patients who have ARDS, and they have an interest in MSCs and came to us, he said.

ARDS is an inflammatory process leading to the build-up of fluid in the lungs and respiratory failure. It can occur due to infection, trauma and inhalation of noxious substances. ARDS often affects previously healthy individuals and accounts for roughly 10% of all ICU admissions, with almost 25% of patients requiring mechanical ventilation. Survivors of ARDS are often left with severe long-term illness and disability.

The study will investigate Cynatas Cymerus MSCs as a treatment for ARDS, in combination with extracorporeal membrane oxygenation (ECMO). ECMO circulates blood through an artificial lung, oxygenating the blood before putting it back into the bloodstream of a patient. ECMO has emerged as a treatment adjunct to support the vital organs in patients with severe ARDS, which can provide short- to medium-term mechanical pulmonary support.

MSC therapy could be used as a possible treatment for ARDS due to the ability of MSCs to reduce inflammation, enhance clearance of pathogens and stimulate tissue repair.

The study will first seek to determine if Cymerus MSC treatment improves oxygenation in sheep with ARDS supported by ECMO, and to evaluate the effects on lung mechanics, blood flow, inflammation and lung injury, as well as safety.

If the study is successful, the data would support progression to a clinical trial of Cymerus MSCs in humans with ARDS undergoing ECMO support.

The study is being funded by the Queensland State Government, the National Health and Medical Research Council (NHMRC), the Intensive Care Society UK, and the Prince Charles Hospital Foundation.

If the FDA or TGA wants us to step in, were all ears. Our product is manufactured in the United States, and supply is not an issue. In theory, were ready to go, Macdonald said.

He was quick to point out that what differentiates Cynatas stem cell product from competitors is that its MSCs are derived from induced pluripotent stem cells (iPSCs), and most stem cell companies rely on multiple donors to donate either bone marrow or adipose tissue as their primary tissue sources. From those sources they derive a small number of MSCs, which represent the starting material of their manufacturing process.

Cynatas Cymerus MSC therapy comes from a single donor and can be produced in limitless quantities, giving it the potential to create a new standard, Macdonald said. The platform technology is based on versatile stem cells known as mesenchymoangioblasts (MCAs), which are a precursor of mesenchymal stem cells.

That process allows the company to make MSCs derived from iPSCs in large amounts without losing their potency, and that forms the basis for the companys platform technology, which it calls Cymerus.

Cynata is gearing up for three phase II trials with its Cymerus MSCs in graft-vs.-host disease (GVHD), critical limb ischemia and osteoarthritis.

Mesoblasts remestemcel-L is being studied in clinical trials across several inflammatory conditions, including in elderly patients with lung disease and adults and children with steroid-refractory aGVHD, heart failure and chronic low back pain due to intervertebral disc degeneration.

The FDA recently accepted Mesoblasts BLA for priority review for remestemcel-L for children with aGVHD. It has a PDUFA date of Sept. 30 for the product branded as Ryoncil.

Mesoblast shares (ASX:MSB) were up nearly 34% to AU$1.78 from AU$1.32 per share by market close April 6.

Cynatas shares (ASX:CYP) were trading at AU86 cents on April 7.

Read more from the original source:
MSC-based therapies from Mesoblast, Cynata advance to tackle COVID-19 ARDS - BioWorld Online

So today Id like to talk about some of the other anti-coronativirus possibilities that I havent gone into yet these posts will never make a comprehensive list, but at least I can cover some of the more interesting ideas, I hope.

Interleukin-6 is an interesting story. This preprint from German researchers presents some evidence that IL-6 levels correlate with the likelihood of severe respiratory symptoms in coronavirus-infected patients: the more IL-6, the worse the outlook. That makes sense, because the protein is already well-established as a big player in immune and inflammation pathways. The question is whether in some patients the immune response gets out of hand; theres a very real chance that many of the worst outcomes are as much a problem with a patients reaction to the viral infection rather than the infection per se. There were early indications of this in the epidemic; this is the cytokine storm that you hear about so much these days, and the remedy for such a situation is to try to turn the immune signaling back down.

Anti-IL-6 antibody therapies have been developed for just that purpose, for patients with autoimmune disorders who need to turn the dial down in just that manner. Rheumatoid arthritis patients generally have elevated IL-6, for example, and tocilizumab (brand name Actemra) was approved by the FDA in 2010 as a therapy. Its since picked up other indications, such as use in cytokine release syndrome, a similar over-stimulation that can show up as a complication in the new CAR-T engineered T-cell therapies for cancer. So its use in the current epidemic seems like a reasonable idea. Its been approved for that purpose in China, there are anecdotal reports from there, from Italy and from other areas, and there are trials underway or planned in China, Switzerland, the US, Belgium, Greece, and Denmark at the very least. Theres another anti IL-6 antibody that was approved in 2017 (sarilumab, brand name Kevzara), and that one is also going into coronavirus trials.

Update: via the comments, there also siltuximab (brand name Sylvant), an antibody which targets the IL-6 protein itself rather than receptor, as the two above do. Its also being looked at in the clinic, and itll be interesting to see if there are different effects, since some of these proteins have functions beyond those mediated by their receptors.

A similar possibility is anakinra (brand name Kineret), which targets the IL-1 system. Interleukin-1 is also a big player in the immune response, and unraveling its complexities is an ongoing project, since there are 11 related interleukins in that family (isnt immunology great?) But they generally work through a limited set of IL receptors, and theres even a natural antagonist protein (IL-1R) that blocks one of them. Anakinra is a modified version of that antagonist, and its also in trials (in fact, its an arm of some of the same trials investigating the IL-6 antibody).And there are other ways to target the response. Heres a proposal to use antagonists of the alpha-1 adrenergic receptor such as prazosin, and heres oneto try low-molecular weight heparin. Sphingosine kinase 2 is involved in inflammation signaling, and an investigational inhibitor of the enzyme (opaganib) is being tried in Italy. Ruxolitinib (brand name Jakavi) is a Janus kinase inhibitor that also affects these pathways and is being looked at as well. Theres even a technique to filter out such signaling molecules from the blood thats getting a look.

Obviously turning down the inflammation response if there arent signs of overstimulatory trouble would (youd think) be a bad idea. Many of these drugs carry warning labels on them already about not using them during acute infections or noting that they can increase the risk of one. But if overstimulation of the immune response really is the problem, this approach could be just whats needed. Picking out the patients that will benefit will be the tricky part!

See original here:
More Therapeutic Ideas for the Coronavirus: Too Much Inflammation? - Science Magazine

WARREN, N.J., April 9, 2020 /PRNewswire/ --Celularity Inc. ("Celularity" or the "Company"), a clinical-stage company developing allogeneic cellular therapies from human placentas, today announced the expansion of its existing collaborative license agreement with United Therapeutics Corporation's (Nasdaq: UTHR) wholly-owned subsidiary, Lung Biotechnology PBC, to include the treatment of COVID-19 and Acute Respiratory Distress Syndrome (ARDS).

This announcement builds on recent pioneering work by Celularity for the use of its proprietary CYNK-001 for the treatment of the SARS-CoV-2 virus that causes the coronavirus disease, COVID-19, and extends this application of the technology to ARDS. The U.S. Food and Drug Administration recently cleared Celularity's investigational new drug application (IND 019650) to evaluate CYNK-001's safety, tolerability, and efficacy for the treatment of COVID-19.

ARDS, the most devastating complication of COVID-19, is a serious inflammatory lung injury that causes hypoxemia, or below-normal oxygen level in the blood. Hypoxemia can lead to multi-organ system failure and death. Recent findings indicate that ARDS may develop in as many as 17-29% of COVID-19 patients who are hospitalized with pneumonia.

Celularity founder and Chief Executive Officer, Dr. Robert Hariri, said, "This promising, novel approach to treating COVID-19 and the pulmonary complications associated with this infection may unlock a powerful new therapeutic option for patients. The exceptional expertise in pulmonary disease, cellular medicine, and manufacturing makes this strategic collaboration particularly well suited to tackle this urgent, global medical crisis."

Under the amended collaborative agreement, Celularity will seek regulatory approval for CYNK-001 in COVID-19, and Lung Biotechnology will seek regulatory approval for CYNK-001 in ARDS. Lung Biotechnology has global rights under the amended collaborative agreement to commercialize CYNK-001 in COVID-19 and ARDS. The collaboration will be governed by a Joint Steering Committee to oversee development and commercialization activities. Financial terms were not disclosed.

Celularity's CYNK-001 is the only cryopreserved allogeneic, off-the-shelf Natural Killer (NK) cell therapy being developed from placental hematopoietic stem cells and is being investigated as a potential treatment option for various hematologic cancers and solid tumors, and is the first cell therapy granted an IND to treat COVID-19. NK cells are a unique class of immune cells, innately capable of targeting cancer cells and virally infected cells and interacting with adaptive immunity. CYNK-001 cells derived from the postpartum placenta have been shown to be well-tolerated in early clinical trials and are currently being investigated as a treatment for acute myeloid leukemia (AML), multiple myeloma (MM), and glioblastoma multiforme (GBM).

Media and Investor RelationsMedia Contact:Factory PR[emailprotected]

Investor Relations Contact:John R. Haines, Executive Vice President[emailprotected]

About Celularity: Celularity, headquartered in Warren, N.J., is a clinical-stage cell therapeutics company delivering transformative allogeneic cellular therapies derived from the postpartum human placenta. Using proprietary technology in combination with its IMPACT platform, Celularity is the only company harnessing the purity and versatility of placental-derived cells to develop and manufacture innovative and highly scalable off-the-shelf treatments for patients with cancer, inflammatory, infectious, and age-related diseases. To learn more, please visit http://www.celularity.com.

Forward-Looking Statements: This press release contains forward-looking statements. These forward-looking statements are based on expectations and are subject to certain factors, risks, and uncertainties that may cause actual results, the outcome of events, timing and performance to differ materially from those expressed or implied by such statements. The information contained in this press release is believed to be current as of the date of the original issue. Celularity expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

SOURCE Celularity Inc.

Home

The rest is here:
Celularity Expands Strategic Collaboration with United Therapeutics Corporation to COVID-19 Infection and Acute Respiratory Distress Syndrome -...

ANKARA

Apheresis therapy can be widely beneficial in treating patients with the novel coronavirus, the president of the World Apheresis Association said Wednesday.

Speaking on convalescent plasma therapy, Fevzi Altuntas said this therapy is being successfully applied in many scientific areas of therapeutic apheresis in Turkey.

What is apheresis?

Apheresis is a science that deals with the processing of blood outside of the body to cure a disease and obtaining the desired blood component or stem cell or cellular therapy products, Altuntas said.

Apheresis is a treatment method that has been successfully applied in treating a wide range of diseases that concern a lot of disciplines such as blood diseases, nephrology, neurology, intensive care, emergency medicine, microbiology and clinical infection, he said.

Stressing that apheresis therapy is not applied only for plasma production in patients with the coronavirus, he said in the pandemic, apheresis is also applied for removal of the virus, the released cytokines and chemicals, replacing the coagulation proteins consumed and the collection of plasma of people who have recovered from COVID-19 disease for transfer.

Turkey started applying convalescent plasma therapy faster than many developed countries, he said.

"This situation sums up the success that our country has reached in the field of apheresis science."

What is convalescent plasma therapy?

This passive antibody therapy is aimed at transferring antibodies to a person for the purpose of protecting and treating against disease, Altuntas underlined.

The aim of the therapy is to take antibodies from the blood of a person who has recovered from a virus and transfer them to a sick person, he said.

In this way, the virus in the patient is expected to be deactivated.

Process of therapy

Commenting on the process of therapy, Altuntas said all donors must be diagnosed with COVID-19.

Donors should have no complaints and feel good for at least 14 days after recovery, he said, stressing that legally, people between the ages of 18-60 can be donors.

He went on to say that immunized plasmas are collected from individuals who meet these criteria and stored in blood banks.

Product collection in apheresis center

Speaking on how to collect products at an apheresis center, Altuntas said the apheresis process will take an average of 60-80 minutes. Approximately 200-600 cc of plasma will be collected with apheresis devices.

Also, the donor will be kept under surveillance for 15 minutes after the transaction is completed, he said, adding an appointment for a new plasma donation will be made again with the consent of the donor.

What will happen to collected products?

Touching on the process after collecting the products, Altuntas said barcoding will be done by the Turkish Red Crescent, also known as Kizilay, for the collected products.

Barcoded products will be stored at minus 18-25 degrees or below in a separate storage cabinet, he said, adding convalescent plasma will be transplanted to severe and critical COVID-19 patients.

Finally, 200-400 ml of convalescent plasma will be transplanted to selected patients, he said.

"I invite everyone recovering from this disease to become a volunteer plasma donor. This is not only a social responsibility but a national duty.

Our examples of social solidarity such as plasma donation are crucial to overcoming this fight together healthfully," he added.

The rest is here:
Convalescent plasma therapy useful in treating COVID-19 - Anadolu Ajans

Analysis Report on Cell Therapy Technologies Market

A report on global Cell Therapy Technologies market has hit stands. This study is based on different aspects like segments, growth rate, revenue, leading players, regions, and forecast. The overall market is getting bigger at an increased pace due to the invention of the new dynamism, which is making rapid progress.

The given report is an excellent research study specially compiled to provide latest insights into critical aspects of the Global Cell Therapy Technologies Market.

Request Sample Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2039749&source=atm

Some key points of Cell Therapy Technologies Market research report:

Strategic Developments: The custom analysis gives the key strategic developments of the market, comprising R&D, new product launch, growth rate, collaborations, partnerships, joint ventures, and regional growth of the leading competitors operating in the market on a global and regional scale.

Market Features: The report comprises market features, capacity, capacity utilization rate, revenue, price, gross, production, production rate, consumption, import, export, supply, demand, cost, market share, CAGR, and gross margin. In addition, the report offers a comprehensive study of the market dynamics and their latest trends, along with market segments and sub-segments.

Analytical Tools: The Global Cell Therapy Technologies Market report includes the accurately studied and assessed data of the key industry players and their scope in the market by means of a number of analytical tools. The analytical tools such as Porters five forces analysis, feasibility study, and many other market research tools have been used to analyze the growth of the key players operating in the market.

Key Manufacturers

The global Cell Therapy Technologies market segment by manufacturers include

The key players covered in this studyDanaherThermo Fisher ScientificMerckTerumoBDLonza GroupGE HealthcareSartoriusStemcell TechnologiesMiltenyi Biotec

Market segment by Type, the product can be split intoEquipmentConsumablesOthers

Market segment by Application, split intoHumanAnimal

Market segment by Regions/Countries, this report coversUnited StatesEuropeChinaJapanSoutheast AsiaIndiaCentral & South America

Make An EnquiryAbout This Report @ https://www.marketresearchhub.com/enquiry.php?type=E&repid=2039749&source=atm

The following points are presented in the report:

Cell Therapy Technologies research provides enterprises a list for selecting the expansion.

Illustrates threatening contracts, as well as, Cell Therapy Technologies impending relation among material providers and vendors and vendors.

In this report, surfaces of Cell Therapy Technologies industry and success are functioned.

The most important research is skilled Cell Therapy Technologies SWOT (Strengths, Weaknesses, Opportunities, and Risks) and PESTEL (Political, Economic, Social, Technological, Environmental and Legal).

The report focuses on Import/send-out detail, Cell Therapy Technologies type analysis, and prediction planning and approaches profit, apart from the technological progress of manufacturers.

Moreover, the report highlighted revenue, sales, manufacturing cost, and product and the States that are most competitive in the lucrative market share idea. There is a discussion on the background and financial trouble in the global Cell Therapy Technologies economic market. This included the CAGR value during the outlook period leading to 2025.

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2039749&licType=S&source=atm

Benefits of Purchasing Cell Therapy Technologies Market Report:

Inimitable Expertise: Analysts will provide deep insights into the reports.

Analyst Support: Get your query resolved from our team before and after purchasing the report.

Customers Satisfaction: Our team will assist with all your research needs and customize the report.

Assured Quality: We focus on the quality and accuracy of the report.

Conclusively, this report will provide you a clear view of each and every fact of the market without a need to refer to any other research report or a data source. Our report will provide you with all the facts about the past, present, and future of the concerned Market.

Read the original:
Cell Therapy Technologies Market Size, Key Trends, Challenges and Standardization, Research, Key Players, Economic Impact and Forecast to 2026 -...

DetailsCategory: DNA RNA and CellsPublished on Tuesday, 07 April 2020 18:42Hits: 254

InGeneron announces publication of favorable results using regenerative cells isolated from patients own body fat prepared with the Transpose RT System in the Journal of Orthopaedic Surgery and Research.

HOUSTON, TX, USA I April 07, 2020 I Results of a U.S. FDA-approved, randomized controlled feasibility study on treatment of symptomatic partial-thickness rotator cuff tears (sPTRCT) with fresh, uncultured, unmodified, autologous adipose-derived regenerative cells (UA-ADRCs) are now available in the Journal of Orthopaedic Surgery and Research.

This prospective multicenter feasibility study performed by Sanford Health is the first randomized controlled trial in which cells isolated from patients own adipose tissue were compared to another therapy option for treating sPTRCT. Specifically, subacromial injection of corticosteroid was compared to injection of UA-ADRCs isolated from the subjects' own adipose tissue using InGeneron's Transpose RT System. Assessment at 24 and 52 weeks post treatment demonstrated significantly higher mean American Shoulder and Elbow Surgeons Standardized Shoulder Assessment Form (ASES) total scores (indicating reduced pain and improved shoulder function) of the subjects in the UA-ADRC group compared to the subjects in the corticosteroid group at both time points. Additionally, there were no significant complications or adverse events associated with the injection of UA-ADRCs during a period of twelve months post treatment, with 20% of the subjects in the corticosteroid group experiencing full-thickness rotator cuff tears during the same period post treatment.

Based on the positive outcome of this feasibility study, InGeneron is currently enrolling a multi-center (up to 20 sites), nationwide FDA IDE pivotal study involving a significantly larger number of patients than the feasibility study (ClinicalTrials.gov Identifier: NCT03752827).

Symptomatic partial-thickness rotator cuff tears (sPTRCT) are among the most common injuries and ailments of the shoulder, especially in elderly patients. Subacromial corticosteroid injection, one of the standard therapies for sPTRCT, often leads to a temporary improvement in clinical symptoms, but not a cure. Furthermore, repeated subacromial corticosteroid injections were reported to be detrimental to tendon healing.

The study shows that unmodified, autologous ADRCs isolated from patients' own adipose tissue at point-of-care using InGenerons Transpose RT System represent a powerful and highly innovative alternative for treating symptomatic PTRCT, said Dr. John Furia, a board-certified orthopedic surgeon, who along with Dr. Nicola Maffulli (London, UK) served as clinical and scientific advisors. Injection of ADRCs into diseased tendons has the potential to jump-start the human response. The science is catching up with the hype and Im optimistic this modality will play an important role in how we treat our patients going forward."

The complete results of the study, entitled Safety and efficacy of treating symptomatic, partial-thickness rotator cuff tears with fresh, uncultured, unmodified, autologous adipose-derived regenerative cells (UA-ADRCs) isolated at the point of care: a prospective, randomized, controlled first-in-human pilot study, (DOI: https://doi.org/10.1186/s13018-020-01631-8) were published in the Journal of Orthopaedic Surgery and Research on March 30, 2020.

About the Transpose RT System and FDA approved clinical trials

InGeneron has developed the Transpose RT System, which consists of a processing unit, a set of disposables and Matrase, a unique enzyme mixture. The system allows isolation of UA-ADRCs from patients' own adipose tissue at point of care within approximately one hour. The UA-ADRCs are administered into the defect by injection under ultrasound guidance.

The Transpose RT System is currently being investigated under FDA IDE approval and accessible for research use only in the US. Currently, InGeneron has several active, FDA approved clinical trials utilizing the Transpose RT System that are enrolling. More information on these clinical trials can be found at http://www.clinicaltrials.gov under the identifiers NCT03752827, NCT03513731, and NCT03503305.

About InGeneron

InGeneron is a clinical stage cell therapy company enabling novel, safe and evidence-based regenerative medicine therapies. Our purpose is to set new therapeutic standards by developing treatments that unlock the healing potential of each patients own regenerative cells processed at the point of care for same-day application. We focus on helping patients who are impacted by musculoskeletal indications and are pursuing research to extend the application of our platform technology to additional treatment areas. http://www.ingeneron.com

SOURCE: InGeneron

Original post:
FDA-Approved Randomized Controlled Feasibility Study Finds InGeneron's Regenerative Cell Therapy to Significantly Reduce Pain and Improve Shoulder...

The report titled Global Cell Freezing Media for Cell Therapy Market is one of the most comprehensive and important additions to QY Researchs archive of market research studies. It offers detailed research and analysis of key aspects of the global Cell Freezing Media for Cell Therapy market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the global Cell Freezing Media for Cell Therapy market. Market participants can use the analysis on market dynamics to plan effective growth strategies and prepare for future challenges beforehand. Each trend of the global Cell Freezing Media for Cell Therapy market is carefully analyzed and researched about by the market analysts.

Key companies operating in the global Cell Freezing Media for Cell Therapymarket include_BioLife Solutions, Thermo Fisher Scientific, Merck, GE Healthcare, Zenoaq, WAK-Chemie Medical, Biological Industries, Akron Biotechnology

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1548125/global-cell-freezing-media-for-cell-therapy-market

Segmental Analysis :

The report has classified the global Cell Freezing Media for Cell Therapy industry into segments including product type and application. Every segment is evaluated based on growth rate and share. Besides, the analysts have studied the potential regions that may prove rewarding for the Cell Freezing Media for Cell Therapy manufcaturers in the coming years. The regional analysis includes reliable predictions on value and volume, thereby helping market players to gain deep insights into the overall Cell Freezing Media for Cell Therapy industry.

Global Cell Freezing Media for Cell Therapy Market Segment By Type:

With FBS, Without FBS

Global Cell Freezing Media for Cell Therapy Market Segment By Applications:

Human Embryonic Stem Cells, CAR-T Cell Therapy, Neural Stem Cell Therapy, Mesenchymal Stem Cell Therapy, Hematopoietic Stem Cell Transplantation, Other

Critical questions addressed by the Cell Freezing Media for Cell Therapy Market report

Reasons to Buy the Report

Get Full Customize report now at :https://www.qyresearch.com/customize-request/form/1548125/global-cell-freezing-media-for-cell-therapy-market

Table of Contents1 Cell Freezing Media for Cell Therapy Market Overview1.1 Cell Freezing Media for Cell Therapy Product Overview1.2 Cell Freezing Media for Cell Therapy Market Segment by Type1.2.1 With FBS1.2.2 Without FBS1.3 Global Cell Freezing Media for Cell Therapy Market Size by Type (2015-2026)1.3.1 Global Cell Freezing Media for Cell Therapy Market Size Overview by Type (2015-2026)1.3.2 Global Cell Freezing Media for Cell Therapy Historic Market Size Review by Type (2015-2020)1.3.2.1 Global Cell Freezing Media for Cell Therapy Sales Market Share Breakdown by Type (2015-2026)1.3.2.2 Global Cell Freezing Media for Cell Therapy Revenue Market Share Breakdown by Type (2015-2026)1.3.2.3 Global Cell Freezing Media for Cell Therapy Average Selling Price (ASP) by Type (2015-2026)1.3.3 Global Cell Freezing Media for Cell Therapy Market Size Forecast by Type (2021-2026)1.3.3.1 Global Cell Freezing Media for Cell Therapy Sales Market Share Breakdown by Application (2021-2026)1.3.3.2 Global Cell Freezing Media for Cell Therapy Revenue Market Share Breakdown by Application (2021-2026)1.3.3.3 Global Cell Freezing Media for Cell Therapy Average Selling Price (ASP) by Application (2021-2026)1.4 Key Regions Market Size Segment by Type (2015-2020)1.4.1 North America Cell Freezing Media for Cell Therapy Sales Breakdown by Type (2015-2026)1.4.2 Europe Cell Freezing Media for Cell Therapy Sales Breakdown by Type (2015-2026)1.4.3 Asia-Pacific Cell Freezing Media for Cell Therapy Sales Breakdown by Type (2015-2026)1.4.4 Latin America Cell Freezing Media for Cell Therapy Sales Breakdown by Type (2015-2026)1.4.5 Middle East and Africa Cell Freezing Media for Cell Therapy Sales Breakdown by Type (2015-2026) 2 Global Cell Freezing Media for Cell Therapy Market Competition by Company2.1 Global Top Players by Cell Freezing Media for Cell Therapy Sales (2015-2020)2.2 Global Top Players by Cell Freezing Media for Cell Therapy Revenue (2015-2020)2.3 Global Top Players Cell Freezing Media for Cell Therapy Average Selling Price (ASP) (2015-2020)2.4 Global Top Manufacturers Cell Freezing Media for Cell Therapy Manufacturing Base Distribution, Sales Area, Product Type2.5 Cell Freezing Media for Cell Therapy Market Competitive Situation and Trends2.5.1 Cell Freezing Media for Cell Therapy Market Concentration Rate (2015-2020)2.5.2 Global 5 and 10 Largest Manufacturers by Cell Freezing Media for Cell Therapy Sales and Revenue in 20192.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Cell Freezing Media for Cell Therapy as of 2019)2.7 Date of Key Manufacturers Enter into Cell Freezing Media for Cell Therapy Market2.8 Key Manufacturers Cell Freezing Media for Cell Therapy Product Offered2.9 Mergers & Acquisitions, Expansion 3 Global Cell Freezing Media for Cell Therapy Status and Outlook by Region (2015-2026)3.1 Global Cell Freezing Media for Cell Therapy Market Size and CAGR by Region: 2015 VS 2020 VS 20263.2 Global Cell Freezing Media for Cell Therapy Market Size Market Share by Region (2015-2020)3.2.1 Global Cell Freezing Media for Cell Therapy Sales Market Share by Region (2015-2020)3.2.2 Global Cell Freezing Media for Cell Therapy Revenue Market Share by Region (2015-2020)3.2.3 Global Cell Freezing Media for Cell Therapy Sales, Revenue, Price and Gross Margin (2015-2020)3.3 Global Cell Freezing Media for Cell Therapy Market Size Market Share by Region (2021-2026)3.3.1 Global Cell Freezing Media for Cell Therapy Sales Market Share by Region (2021-2026)3.3.2 Global Cell Freezing Media for Cell Therapy Revenue Market Share by Region (2021-2026)3.3.3 Global Cell Freezing Media for Cell Therapy Sales, Revenue, Price and Gross Margin (2021-2026)3.4 North America Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)3.4.1 North America Cell Freezing Media for Cell Therapy Revenue YoY Growth (2015-2026)3.4.2 North America Cell Freezing Media for Cell Therapy Sales YoY Growth (2015-2026)3.5 Asia-Pacific Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)3.5.1 Asia-Pacific Cell Freezing Media for Cell Therapy Revenue YoY Growth (2015-2026)3.5.2 Asia-Pacific Cell Freezing Media for Cell Therapy Sales YoY Growth (2015-2026)3.6 Europe Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)3.6.1 Europe Cell Freezing Media for Cell Therapy Revenue YoY Growth (2015-2026)3.6.2 Europe Cell Freezing Media for Cell Therapy Sales YoY Growth (2015-2026)3.7 Latin America Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)3.7.1 Latin America Cell Freezing Media for Cell Therapy Revenue YoY Growth (2015-2026)3.7.2 Latin America Cell Freezing Media for Cell Therapy Sales YoY Growth (2015-2026)3.8 Middle East and Africa Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)3.8.1 Middle East and Africa Cell Freezing Media for Cell Therapy Revenue YoY Growth (2015-2026)3.8.2 Middle East and Africa Cell Freezing Media for Cell Therapy Sales YoY Growth (2015-2026) 4 Global Cell Freezing Media for Cell Therapy by Application4.1 Cell Freezing Media for Cell Therapy Segment by Application4.1.1 Human Embryonic Stem Cells4.1.2 CAR-T Cell Therapy4.1.3 Neural Stem Cell Therapy4.1.4 Mesenchymal Stem Cell Therapy4.1.5 Hematopoietic Stem Cell Transplantation4.1.6 Other4.2 Global Cell Freezing Media for Cell Therapy Sales by Application: 2015 VS 2020 VS 20264.3 Global Cell Freezing Media for Cell Therapy Historic Sales by Application (2015-2020)4.4 Global Cell Freezing Media for Cell Therapy Forecasted Sales by Application (2021-2026)4.5 Key Regions Cell Freezing Media for Cell Therapy Market Size by Application4.5.1 North America Cell Freezing Media for Cell Therapy by Application4.5.2 Europe Cell Freezing Media for Cell Therapy by Application4.5.3 Asia-Pacific Cell Freezing Media for Cell Therapy by Application4.5.4 Latin America Cell Freezing Media for Cell Therapy by Application4.5.5 Middle East and Africa Cell Freezing Media for Cell Therapy by Application 5 North America Cell Freezing Media for Cell Therapy Market Size by Country (2015-2026)5.1 North America Market Size Market Share by Country (2015-2020)5.1.1 North America Cell Freezing Media for Cell Therapy Sales Market Share by Country (2015-2020)5.1.2 North America Cell Freezing Media for Cell Therapy Revenue Market Share by Country (2015-2020)5.2 North America Market Size Market Share by Country (2021-2026)5.2.1 North America Cell Freezing Media for Cell Therapy Sales Market Share by Country (2021-2026)5.2.2 North America Cell Freezing Media for Cell Therapy Revenue Market Share by Country (2021-2026)5.3 North America Market Size YoY Growth by Country5.3.1 U.S. Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)5.3.2 Canada Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026) 6 Europe Cell Freezing Media for Cell Therapy Market Size by Country (2015-2026)6.1 Europe Market Size Market Share by Country (2015-2020)6.1.1 Europe Cell Freezing Media for Cell Therapy Sales Market Share by Country (2015-2020)6.1.2 Europe Cell Freezing Media for Cell Therapy Revenue Market Share by Country (2015-2020)6.2 Europe Market Size Market Share by Country (2021-2026)6.2.1 Europe Cell Freezing Media for Cell Therapy Sales Market Share by Country (2021-2026)6.2.2 Europe Cell Freezing Media for Cell Therapy Revenue Market Share by Country (2021-2026)6.3 Europe Market Size YoY Growth by Country6.3.1 Germany Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)6.3.2 France Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)6.3.3 U.K. Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)6.3.4 Italy Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)6.3.5 Russia Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026) 7 Asia-Pacific Cell Freezing Media for Cell Therapy Market Size by Country (2015-2026)7.1 Asia-Pacific Market Size Market Share by Country (2015-2020)7.1.1 Asia-Pacific Cell Freezing Media for Cell Therapy Sales Market Share by Country (2015-2020)7.1.2 Asia-Pacific Cell Freezing Media for Cell Therapy Revenue Market Share by Country (2015-2020)7.2 Asia-Pacific Market Size Market Share by Country (2021-2026)7.2.1 Asia-Pacific Cell Freezing Media for Cell Therapy Sales Market Share by Country (2021-2026)7.2.2 Asia-Pacific Cell Freezing Media for Cell Therapy Revenue Market Share by Country (2021-2026)7.3 Asia-Pacific Market Size YoY Growth by Country7.3.1 China Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)7.3.2 Japan Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)7.3.3 South Korea Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)7.3.4 India Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)7.3.5 Australia Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)7.3.6 Taiwan Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)7.3.7 Indonesia Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)7.3.8 Thailand Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)7.3.9 Malaysia Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)7.3.10 Philippines Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)7.3.11 Vietnam Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026) 8 Latin America Cell Freezing Media for Cell Therapy Market Size by Country (2015-2026)8.1 Latin America Market Size Market Share by Country (2015-2020)8.1.1 Latin America Cell Freezing Media for Cell Therapy Sales Market Share by Country (2015-2020)8.1.2 Latin America Cell Freezing Media for Cell Therapy Revenue Market Share by Country (2015-2020)8.2 Latin America Market Size Market Share by Country (2021-2026)8.2.1 Latin America Cell Freezing Media for Cell Therapy Sales Market Share by Country (2021-2026)8.2.2 Latin America Cell Freezing Media for Cell Therapy Revenue Market Share by Country (2021-2026)8.3 Latin America Market Size YoY Growth by Country8.3.1 Mexico Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)8.3.2 Brazil Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)8.3.3 Argentina Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026) 9 Middle East and Africa Cell Freezing Media for Cell Therapy Market Size by Country (2015-2026)9.1 Middle East and Africa Market Size Market Share by Country (2015-2020)9.1.1 Middle East and Africa Cell Freezing Media for Cell Therapy Sales Market Share by Country (2015-2020)9.1.2 Middle East and Africa Cell Freezing Media for Cell Therapy Revenue Market Share by Country (2015-2020)9.2 Middle East and Africa Market Size Market Share by Country (2021-2026)9.2.1 Middle East and Africa Cell Freezing Media for Cell Therapy Sales Market Share by Country (2021-2026)9.2.2 Middle East and Africa Cell Freezing Media for Cell Therapy Revenue Market Share by Country (2021-2026)9.3 Middle East and Africa Market Size YoY Growth by Country9.3.1 Turkey Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)9.3.2 Saudi Arabia Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)9.3.3 U.A.E Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026) 10 Company Profiles and Key Figures in Cell Freezing Media for Cell Therapy Business10.1 BioLife Solutions10.1.1 BioLife Solutions Corporation Information10.1.2 BioLife Solutions Description, Business Overview and Total Revenue10.1.3 BioLife Solutions Cell Freezing Media for Cell Therapy Sales, Revenue and Gross Margin (2015-2020)10.1.4 BioLife Solutions Cell Freezing Media for Cell Therapy Products Offered10.1.5 BioLife Solutions Recent Development10.2 Thermo Fisher Scientific10.2.1 Thermo Fisher Scientific Corporation Information10.2.2 Thermo Fisher Scientific Description, Business Overview and Total Revenue10.2.3 Thermo Fisher Scientific Cell Freezing Media for Cell Therapy Sales, Revenue and Gross Margin (2015-2020)10.2.5 Thermo Fisher Scientific Recent Development10.3 Merck10.3.1 Merck Corporation Information10.3.2 Merck Description, Business Overview and Total Revenue10.3.3 Merck Cell Freezing Media for Cell Therapy Sales, Revenue and Gross Margin (2015-2020)10.3.4 Merck Cell Freezing Media for Cell Therapy Products Offered10.3.5 Merck Recent Development10.4 GE Healthcare10.4.1 GE Healthcare Corporation Information10.4.2 GE Healthcare Description, Business Overview and Total Revenue10.4.3 GE Healthcare Cell Freezing Media for Cell Therapy Sales, Revenue and Gross Margin (2015-2020)10.4.4 GE Healthcare Cell Freezing Media for Cell Therapy Products Offered10.4.5 GE Healthcare Recent Development10.5 Zenoaq10.5.1 Zenoaq Corporation Information10.5.2 Zenoaq Description, Business Overview and Total Revenue10.5.3 Zenoaq Cell Freezing Media for Cell Therapy Sales, Revenue and Gross Margin (2015-2020)10.5.4 Zenoaq Cell Freezing Media for Cell Therapy Products Offered10.5.5 Zenoaq Recent Development10.6 WAK-Chemie Medical10.6.1 WAK-Chemie Medical Corporation Information10.6.2 WAK-Chemie Medical Description, Business Overview and Total Revenue10.6.3 WAK-Chemie Medical Cell Freezing Media for Cell Therapy Sales, Revenue and Gross Margin (2015-2020)10.6.4 WAK-Chemie Medical Cell Freezing Media for Cell Therapy Products Offered10.6.5 WAK-Chemie Medical Recent Development10.7 Biological Industries10.7.1 Biological Industries Corporation Information10.7.2 Biological Industries Description, Business Overview and Total Revenue10.7.3 Biological Industries Cell Freezing Media for Cell Therapy Sales, Revenue and Gross Margin (2015-2020)10.7.4 Biological Industries Cell Freezing Media for Cell Therapy Products Offered10.7.5 Biological Industries Recent Development10.8 Akron Biotechnology10.8.1 Akron Biotechnology Corporation Information10.8.2 Akron Biotechnology Description, Business Overview and Total Revenue10.8.3 Akron Biotechnology Cell Freezing Media for Cell Therapy Sales, Revenue and Gross Margin (2015-2020)10.8.4 Akron Biotechnology Cell Freezing Media for Cell Therapy Products Offered10.8.5 Akron Biotechnology Recent Development 11 Cell Freezing Media for Cell Therapy Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis11.1 Cell Freezing Media for Cell Therapy Key Raw Materials11.1.1 Key Raw Materials11.1.2 Key Raw Materials Price11.1.3 Raw Materials Key Suppliers11.2 Manufacturing Cost Structure11.2.1 Raw Materials11.2.2 Labor Cost11.2.3 Manufacturing Expenses11.3 Cell Freezing Media for Cell Therapy Industrial Chain Analysis11.4 Market Opportunities, Challenges, Risks and Influences Factors Analysis11.4.1 Market Opportunities and Drivers11.4.2 Market Challenges11.4.3 Market Risks11.4.4 Porters Five Forces Analysis 12 Market Strategy Analysis, Distributors12.1 Sales Channel12.2 Distributors12.3 Downstream Customers 13 Research Findings and Conclusion 14 Appendix14.1 Methodology/Research Approach14.1.1 Research Programs/Design14.1.2 Market Size Estimation14.1.3 Market Breakdown and Data Triangulation14.2 Data Source14.2.1 Secondary Sources14.2.2 Primary Sources14.3 Author Details14.4 Disclaimer

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

View original post here:
Covid-19 Impact on Cell Freezing Media for Cell Therapy Market (2020-2026) - Science In Me

TORONTO , April 7, 2020 /CNW/ - panCELLa is pleased to announce that it will receive advisory services and up to $400,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to help further research and development of its technology platforms for cell therapy.

panCELLa Inc (CNW Group/panCELLa Inc.)

Support from NRC IRAP will go toward the research and development of a two-step safety switch known as panKiller. While panCELLa's safety switch, known as FailSafeTM, is specifically designed to eliminate only "rogue" or deregulated therapeutic cells, the panKiller system further enhances this platform and provides a means to remove a graft entirely once it has fulfilled its therapeutic purpose. When the therapeutic cells are no longer required, and to avoid serious adverse events, for further safety measures they would be eliminated using panKiller. The panKiller strategy is an effective solution that addresses serious limitations of current cell therapies which involve removal of these therapeutic cells through irradiation. panKiller will enable more prolonged, effective treatment in vivo; and will destroy the therapeutic cells at the appropriate time without the use of radiation to prevent the possibility of a malignancy.

About panCELLa

Founded in 2015, panCELLa is a privately-held early-stage biotechnology firm based on the innovative technology developed in Dr. Andras Nagy's lab at the Sinai Health System (SHS). panCELLa has created platforms that allow for the development of safe, universal, cost-effective, "off-the-shelf" cell lines. panCELLa's mandate is to accelerate cell-based therapies to a broad range of diseases by providing safe therapeutic cell products. panCELLa has secured partnerships with several biotechnology partners to enhance its patent position and provide expanded access to its exclusive FailSafeTM and Stealth CellsTM and its in-licensed SAFE harbor technology. panCELLa aims to develop therapeutic products in the immunology, mesenchymal stem cell and pancreatic islet space and to partner with other companies to develop novel products in other areas of regenerative medicine. panCELLa continues its internal R&D efforts to develop additional novel uses of its platform technologies in areas such as bio-production, cancer vaccination and tolerization. To learn more about panCELLa's FailSafeTM and induced Allogeneic Cell Tolerance, please visit https://pancella.com

SOURCE panCELLa Inc.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/April2020/07/c5756.html

See more here:
panCELLa receives research and development support for cell therapy - Yahoo Finance